Skip to main content

Table 1 Patient and treatment characteristics of cases and controls

From: Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy

 

Cases N = 26 (%)

Controls N = 44 (%)

Total N = 70 (%)

Comparison of cases & controls p-value

Age when blood sample taken

66.3 (9.4)

65.5 (7.0)

65.8 (7.9)

0.7202

(years): Mean (SD)

Time since radiotherapy

10.2 (1.2)

9.8 (0.8)

9.9 (0.9)

0.1432

(years): Mean (SD)

Radiotherapy schedule

   

0.141

50 Gy in 25Fr

10 (38.5)

9 (20.4)

19 (27.1)

41.6 Gy in 13Fr

11 (42.3)

18 (40.9)

29 (41.4)

39 Gy in 13Fr

5 (19.2)

17 (38.6)

22 (31.4)

Tumour bed boost

   

0.6643

No

3 (11.5)

3 (6.8)

6 (13.6)

Yes

23 (88.5)

41 (93.2)

64 (91.4)

Lymphatic radiotherapy

   

0.7513,4

None

21 (80.8)

37 (84.1)

58 (82.9)

Axilla only

0 (0)

0 (0)

0 (0)

SCF only

5 (19.2)

6 (13.6)

11 (15.7)

Axilla and SCF

0 (0)

1 (2.3)

1 (1.4)

Adjuvant chemotherapy

   

0.861

No

17 (65.4)

31 (70.4)

48 (65.6)

Yes

9 (34.6)

13 (29.5)

22 (31.4)

Tamoxifen

   

0.4683

No

2 (7.7)

7 (15.9)

9 (12.9)

Yes

24 (92.3)

37 (84.1)

61 (87.1)

 
  1. SD = standard deviation.
  2. Gy = Gray.
  3. Fr = fractions.
  4. SCF = supraclavicular fossa.
  5. 1p-value from chi-squared test unless otherwise indicated.
  6. 2p-value from t-test.
  7. 3Fisher’s exact test.
  8. 4chi-squared test of none versus any lymphatic radiotherapy.